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Abstract
Background: The most prominent feature of melancholic depression is a near-total loss of the capacity to derive
pleasure from activities or other positive stimuli. Additional symptoms can include psychomotor disturbances, anorexia,
excessive guilt, and early awakening from sleep. Melancholic patients may exhibit treatment responses and outcomes that
differ from those of non-melancholic patients. Pooled data from double-blind, placebo-controlled studies were utilized
to compare the efficacy of duloxetine in depressed patients with and without melancholic features.
Methods: Efficacy data were pooled from 8 double-blind, placebo-controlled clinical trials of duloxetine. The presence
of melancholic features (DSM-IV criteria) was determined using results from the Mini International Neuropsychiatric
Interview (MINI). Patients (aged ≥ 18 years) meeting DSM-IV criteria for major depressive disorder (MDD) received
duloxetine (40–120 mg/d; melancholic, N = 759; non-melancholic, N = 379) or placebo (melancholic, N = 519; non-
melancholic, N = 256) for up to 9 weeks. Efficacy measures included the 17-item Hamilton Rating Scale for Depression
(HAMD17) total score, HAMD17 subscales (Maier, anxiety, retardation, sleep), the Clinical Global Impression of Severity
(CGI-S) and Patient Global Impression of Improvement (PGI-I) scales, and Visual Analog Scales (VAS) for pain.
Results: In data from all 8 studies, duloxetine's advantage over placebo did not differ significantly between melancholic
and non-melancholic patients (treatment-by-melancholic status interactions were not statistically significant). Duloxetine
demonstrated significantly greater improvement in depressive symptom severity, compared with placebo, within both
melancholic and non-melancholic cohorts (p ≤ .001 for HAMD17 total score, CGI-S and PGI-I). When analyzed by gender,
the magnitude of improvement in efficacy outcomes did not differ significantly between duloxetine-treated male and
female melancholic patients. In the two studies that assessed duloxetine 60 mg once-daily dosing, duloxetine-treated
melancholic patients had significantly greater improvement compared with placebo on HAMD17 total score, CGI-S, PGI-
I, 3 of 4 subscales of the HAMD17, and VAS overall pain severity (p < .01). Estimated probabilities of response and
remission were significantly greater for melancholic patients receiving duloxetine 60 mg QD compared with placebo
(response 74.7% vs. 42.2%, respectively, p < .001; remission 44.4% vs. 24.7%, respectively, p = .002
Conclusions: In this analysis of pooled data, the efficacy of duloxetine in patients with melancholic features did not differ
significantly from that observed in non-melancholic patients.
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Background
Although the first appearance of the term "melancholia"
dates back to antiquity[1], its use was in decline until it
was re-adopted in 1980 by the authors of the Diagnostic
and Statistical Manual of Mental Disorders, 3rdEdition (DSM-
III) to describe a subtype of major depressive disorder
(MDD). Although revised in DSM-III-R, the current DSM-
IV "With Melancholic Features Specifier" represents a
return to the older DSM-III definition. According to DSM-
IV criteria, the principal diagnostic feature exhibited by
patients with melancholic depression is a loss of pleasure
in all, or almost all, activities or a lack of reactivity to usu-
ally pleasurable stimuli [2]. Additional symptoms include
diurnal variation (depression worse in the morning), psy-
chomotor disturbances, anorexia, excessive guilt, and
early awakening from sleep. Estimates of the prevalence of
melancholic features among patients diagnosed with
MDD range from 16% to 53% [3-6], although the preva-
lence may be as high as 76% among inpatients [6].
Melancholia is encountered equally in both genders [7],
but is observed more frequently in older patients [4,8].
While melancholia is associated with an increased comor-
bidity of anxiety disorders, panic disorder, and phobia
[9], melancholic patients have a significantly lower sui-
cide rate than non-melancholics [10].
A considerable body of evidence suggests that biological
differences exist between melancholic and non-melan-
cholic depression. The hypercortisolism of melancholia
has been described as perhaps the best documented find-
ing in biological psychiatry[11]. Many of the features
exhibited by melancholic patients closely resemble those
that occur reflexively in non-depressed populations dur-
ing acutely stressful or threatening situations [12]. Thus,
depressed patients with melancholic features consistently
demonstrate an activation of the hypothalamic-pituitary-
adrenocortical (HPA) axis[13], resulting in laboratory
findings of dexamethasone non-suppression. Melan-
cholic patients also have an activated corticotrophin-
releasing hormone (CRH) system and may have dimin-
ished activities of the growth hormone and reproductive
axes[14]. When compared with non-melancholic
depressed patients, melancholics have also been shown to
exhibit lower concentration of nighttime serum mela-
tonin [15], lower plasma serotonin (5-HT) concentrations
[16,17], and an impaired in vivo immune response
[18,19].
Given the distinct clinical and physiological features asso-
ciated with melancholia, it is perhaps not surprising that
melancholic patients may exhibit treatment responses
and outcomes that differ from those of non-melancholic
depressed patients. In reviewing a number of long-term
studies, Parker et al concluded that melancholics appear
to respond well to treatment of individual episodes but
have frequent recurrences, while non-melancholics may
respond less rapidly and less completely in any individual
episode but show a general pattern of improvement over
time [20]. Overall, melancholics appear to have higher
rehospitalization rates and greater illness morbidity over
an extended period [20].
Melancholic patients are less likely to respond to non-spe-
cific supportive therapies, such as cognitive behavior ther-
apy or interpersonal psychotherapy, and more often
require pharmacotherapy to achieve a successful treat-
ment outcome [21,22]. Within the context of clinical tri-
als, this apparent lack of response to non-specific
therapies is frequently manifested in the form of a mark-
edly lower placebo response rate among melancholic,
when compared with non-melancholic, patients [23-27].
Thus, in some studies, antidepressant-treated melancholic
patients have demonstrated significantly greater improve-
ments compared with placebo while a non-melancholic
cohort has failed to achieve separation from placebo.
However, the drug response is usually of similar magni-
tude in all patients, and the difference in outcome can be
traced to significantly different placebo responses within
melancholic and non-melancholic patients [26,28].
Although a number of studies have investigated the rela-
tive efficacy of specific classes of antidepressant medica-
tions in melancholic patients, results have been
somewhat inconsistent [26]. While tricyclic antidepres-
sants (TCAs) have demonstrated superiority over selective
serotonin reuptake inhibitors (SSRIs) in some studies of
melancholic depression [29-32], results from other head-
to-head studies have failed to support these findings [33-
35]. Thus, the current consensus is that SSRIs and TCAs
demonstrate comparable efficacy for the treatment of mel-
ancholic depression [13,36]. With regard to safety and tol-
erability, however, SSRIs offer considerable advantages
since they lack the anticholinergic, antihistaminergic, and
cardiotoxic effects associated with TCAs [37]. As a result,
SSRIs are now recognized as the first-line treatment for
melancholia.
The antidepressant duloxetine is a balanced and potent
dual reuptake inhibitor of 5-HT and norepinephrine
(NE). The efficacy of duloxetine in the treatment of MDD
has been established in randomized, double-blind, pla-
cebo-controlled studies of up to 9 weeks duration [38]. In
the present study, pooled data from 8 clinical trials of
duloxetine were utilized to compare treatment outcomes
in melancholic patients with those in non-melancholic
patients.BMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
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Methods
Study Design
All 8 studies included in these analyses were randomized,
multicenter, double-blind, placebo-controlled clinical tri-
als and represented all of the double-blind studies
included in the New Drug Application reviewed by regu-
latory agencies for duloxetine's indication in MDD. All
studies incorporated double-blind, variable-expected
duration placebo lead-in periods to blind patients and
investigators to the start of active therapy. Six studies also
utilized an active comparator – fluoxetine (20 mg QD) in
Studies 1 and 2, and paroxetine (20 mg QD) in Studies 3,
4, 7, and 8. Study protocols were reviewed and approved
by the ethical review board at each center, in accordance
with the principles of the Declaration of Helsinki, and all
patients provided written informed consent prior to the
administration of any study procedures or study drug. The
numbers of patients randomized in each study are sum-
marized in Table 1. Detailed safety and efficacy results
from Studies 1 [39], 4 [40], 5 [41], and 6 [42] have been
published previously.
Patients
In all studies, patients were 18 years of age or older and
met criteria for MDD as defined by the Diagnostic and Sta-
tistical Manual of Mental Disorders, 4thEdition  (DSM-IV)
[43]. The diagnosis of MDD was confirmed by the Mini
International Neuropsychiatric Interview (MINI) [44], a
standardized diagnostic interview based on DSM-IV crite-
ria. Patients had a 17-item Hamilton Rating Scale for
Depression (HAMD17)[45] total score ≥ 15 and a Clinical
Global Impression of Severity (CGI-S)[46] score ≥ 4 at the
screening and second study visits. The presence of melan-
cholic features (DSM-IV criteria) was determined using
results from the MINI:
"Either feature 1 or 2 in Criteria A AND three (or more) fea-
tures from Criteria B must be present to qualify for melancholic
features.
A. Either of the following, occurring during the most severe
period of the current episode.
1. Loss of pleasure in all, or almost all, activities;
2. Lack of reactivity to usually pleasurable stimuli
B. Three (or more) of the following:
1. Distinct quality of depressed mood;
2. Depression regularly worse in the morning;
3. Early morning awakening (at least 2 hours before usual time
of awakening);
4. Marked psychomotor retardation or agitation;
5. Significant anorexia or weight loss;
6. Excessive or inappropriate guilt."
Patients were excluded for the following reasons: a current
and primary Axis I disorder, other than MDD; an Axis II
disorder which could interfere with protocol compliance;
lack of response of the current depressive episode to two
Table 1: Numbers of randomized patients‡
Study Placebo SSRIa Duloxetine
40 mg/db 60 mg QD 80 mg/dc 120 mg/dd
1 70 (80.0) 33 (72.7) - - - 70 (77.1)
2 74 (73.0) 37 (86.5) - - - 82 (69.5)
3 90 (55.6) 89 (64.0) 91 (62.6) - 84 (60.7) -
4 89 (66.3) 87 (63.2) 86 (72.1) - 91 (69.2) -
5 121 (69.4) - - 122 (63.1) - -
6 139 (62.6) - - 128 (62.5) - -
7 93 (66.7) 86 (68.6) - - 95 (65.3) 93 (66.7)
8 99 (67.7) 97 (69.1) - - 93 (71.0) 103 (66.0)
TOTAL 775 (67.0) 429 (68.5) 1138 (66.7)
‡ Data presented in the form T (% M), where T = total number of patients, % M = percentage of patients with melancholic features
a. SSRI in Studies 1 and 2 is fluoxetine (20 mg QD). SSRI in Studies 3, 4, 7, and 8 is paroxetine (20 mg QD).
b. Administered 20 mg twice-daily (BID)
c. Administered 40 mg BID
d. Administered 60 mg BID. Studies 1 and 2 incorporated a forced titration from 20 mg BID to 60 mg BID.BMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
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or more adequate courses of antidepressant therapy; seri-
ous medical illness; a serious risk of suicide; a history of
substance abuse or dependence within the last year, or a
positive urine drug screen.
Concomitant medications with primarily central nervous
system activity were not permitted, with the exception of
episodic use of chloral hydrate or zolpidem for insomnia.
Chronic use of prescription analgesic medications was not
allowed; episodic use was permitted at the discretion of
the physician in charge of the study. Use of anti-hyperten-
sive medications was not permitted unless the patient had
been on a stable dose for at least 3 months prior to study
entry.
Data Pooling Strategies
Efficacy analyses were performed on three sets of data,
obtained using the following pooling strategies:
(A) "All Studies" – data from all 8 studies were pooled.
Placebo: melancholic (n = 519; 67.0%), non-melancholic
(n = 256; 33.0%). Duloxetine (40–120 mg/d): melan-
cholic (n = 759; 66.7%), non-melancholic (n = 379;
33.3%). Duloxetine was compared with placebo in one
set of analyses. In a second set of analyses using data from
the 6 SSRI-controlled studies, duloxetine was compared
with fluoxetine and paroxetine: Placebo: melancholic (n =
348; 67.6%), non-melancholic (n = 167; 32.4%). Duloxe-
tine (40–120 mg/d): melancholic (n = 602; 67.8%), non-
melancholic (n = 286; 32.2%). SSRI: melancholic (n =
294; 68.5%), non-melancholic (n = 135; 31.5%);
(B) "Positive Studies" – data from placebo- and duloxet-
ine-treated patients were pooled from the 6 studies (1, 4,
5, 6,7, and 8) that demonstrated a significant advantage
for duloxetine over placebo on the primary efficacy meas-
ure. Placebo: melancholic (n = 415; 67.9%), non-melan-
cholic (n = 196; 32.1%). Duloxetine (40–120 mg/d):
melancholic (n = 594; 67.4%), non-melancholic (n = 287;
32.6%);
(C) "Focus Studies" – data were pooled from the 2 studies
(5 and 6) that compared duloxetine 60 mg once-daily
with placebo. Placebo: melancholic (n = 171; 65.8%),
non-melancholic (n = 89; 34.2%). Duloxetine (60 mg/d):
melancholic (n = 157; 62.8%), non-melancholic (n = 93;
37.2%).
Strategy A facilitated assessments of differential efficacy in
the largest possible data set. While the inclusion of all
available data has obvious advantages, the presence of
failed studies could mask differential treatment effects. If
a study failed to detect an overall effect it is unlikely to
help detect differential subgroup effects. Therefore strat-
egy B essentially served as a robustness check for strategy
A. Pooling strategy C facilitated assessments at the recom-
mended target dose.
Efficacy Measures
In all 8 studies, the primary efficacy outcome was mean
change from baseline to endpoint in HAMD17 total score.
Other efficacy measures assessed in all studies included
HAMD17 subscales: anxiety/somatization (Items 10, 11,
12, 13, 15, and 17), Maier (Items 1, 2, 7, 8, 9, and 10),
retardation (Items 1, 7, 8, and 14), and sleep (Items 4, 5,
and 6); the CGI-S scale; and the Patient Global Impression
of Improvement (PGI-I) scale [46]. Response was defined
as a decrease from baseline of at least 50% on the
HAMD17 total score. Remission was defined as a HAMD17
total score ≤ 7. In Studies 3 – 8, the severity of painful
physical symptoms was assessed using Visual Analog
Scales (VAS) for pain [47].
Statistical analyses
Patients with missing melancholia status were not
included in the analyses. All other patients with a baseline
and at least one postbaseline observation were included
in the analyses. Mean changes from baseline to last obser-
vation (carried forward) in HAMD17 total score, CGI-S,
and PGI-I were assessed using an analysis of covariance
(ANCOVA) with models that included baseline score,
treatment, melancholia status (features present Yes/No),
investigator, and the treatment-by-melancholia status
interaction as independent variables. Hereafter this analy-
sis is referred to as LOCF mean change.
The treatment-by-melancholic status interaction was the
main basis upon which differential treatment effects
between the subgroups were assessed. Contrasts between
duloxetine and placebo within the melancholic and non-
melancholic subgroups were used to assess the clinical rel-
evance of treatment effects.
Longitudinal mean changes and categorical changes (esti-
mated probabilities) were assessed using a likelihood-
based mixed-effects model repeated measures (MMRM)
approach. Models for mean changes included treatment,
visit, investigator, baseline HAMD17 value, melancholia
status, and the two-way and three-way interactions
between treatment, visit, and melancholia status. Hereaf-
ter this analysis is referred to as MMRM mean change. The
categorical longitudinal analyses were similar in concept
to the longitudinal mean change analyses, but simplifica-
tions were necessary to reduce the computational
complexity.
The categorical analyses were applied only to patients
with melancholic features so that the main effect of mel-
ancholic status and its two-way and three-way interactions
with visit and treatment could be deleted. Therefore, theBMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
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model for the categorical analyses included treatment,
visit, investigator, baseline HAMD17 value, and the treat-
ment-by-visit interaction. A logit link function and a bino-
mial error structure were included to account for the non-
linearity of the response and the non-normality of the
data, respectively. Hereafter, this analysis is referred to as
categorical MMRM. Remission and response rates at last
observation were assessed using Fisher's Exact test.
The LOCF mean change analysis of HAMD17, CGI-S and
PGI-I was applied to all three databases. The focus for the
analyses was on all studies and the positive studies with
the primary aim of detecting differential effects of duloxe-
tine in patients with and without melancholic features.
The MMRM mean change and categorical MMRM analy-
ses were then applied to a wide variety of outcomes from
the focus studies in order to gain an in-depth perspective
on the efficacy of duloxetine in patients with melancholic
features. In addition, LOCF analyses of data from the
focus studies were conducted in order to assess robustness
of the MMRM results.
Results
Patient characteristics
Baseline patient demographics are summarized in Table
2. The prevalence of melancholic features in the overall
patient population was 67.1% (1572/2342). The melan-
cholic cohort had a significantly higher proportion of
females compared with the non-melancholic group
(69.5% vs. 60.8%, p < .001). Melancholic patients also
had a significantly lower mean body weight than non-
melancholics (77.7 kg vs. 81.3 kg, p < .001). Mean age at
enrollment did not differ significantly between melan-
cholic and non-melancholic patients.
Mean baseline HAMD17 total scores and CGI-S scores
were significantly higher (more severe illness) in melan-
cholic patients compared with non-melancholics
(HAMD17: 22.3 vs. 20.5, p < .001; CGI-S: 4.41 vs. 4.26, p
< .001). There was a marginally significant difference in
VAS overall pain severity at baseline (31.7 vs. 31.0 for
melancholic and non-melancholic groups, respectively; p
= .053), although the clinical relevance of this small dif-
ference is questionable.
Efficacy – All studies and positive studies
Analyses of mean changes from baseline to last observa-
tion (LOCF mean change) from all eight studies and the
six positive studies are summarized in Table 3. In both
melancholic and non-melancholic patients, duloxetine
demonstrated significant advantages over placebo in
HAMD17 total score, CGI-S and PGI-I (p ≤ .001). Treat-
ment-by-melancholic status interactions were not signifi-
cant for HAMD17 total score, CGI-S, or PGI-I, in either
data set (p > .50 for each comparison). Using pooled data
from all studies, the effect size for HAMD17 total score was
0.33 in melancholic patients and 0.32 in non-melan-
cholics. In the six positive studies, the effect size for
HAMD17 total score was 0.39 in melancholic patients
compared with 0.43 in non-melancholics.
Within the subset of melancholic patients, treatment-by-
gender interactions for mean change in HAMD17 total
score, mean change in CGI-S score, and mean endpoint
PGI-I score were not statistically significant, indicating
that duloxetine's efficacy was similar in male and female
melancholic patients (Table 4). In pooled data from all
studies, the effect size for HAMD17 total score was 0.29 in
male melancholic patients compared with 0.35 in female
melancholics. Effect sizes for CGI-S score were 0.35 vs.
Table 2: Baseline demographics and illness severity (all studies)†
Melancholic (N = 1572) Non-melancholic (N = 770) p-value
Gender, n (%)
Female 1092 (69.5) 468 (60.8) <.001
Age, y
Mean (SD) 42.1 (12.2) 43.4 (12.8) .347
Age range
Min – Max 18 – 82 18 – 82 -
Weight, kg
Mean (SD) 77.7 (20.5) 81.3 (21.4) <.001
HAMD17 Total Score
Mean (SD) 22.3 (3.9) 20.5 (3.2) <.001
CGI-Severity
Mean (SD) 4.41 (0.56) 4.26 (0.48) <.001
VAS Overall Pain
Mean (SD) 31.7 (25.3) 31.0 (26.0) .053
† Includes patients from paroxetine and fluoxetine treatment arms (N = 429).BMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
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0.33 for male and female melancholic patients, respec-
tively, while PGI-I effect sizes were 0.26 (males) vs. 0.34
(females).
In melancholic patients, treatment-by-age interactions for
mean change in HAMD17 total score were not significant
at thresholds of age 55 (p = .777), age 60 (p = .387), or age
65 (p = .540), indicating that the efficacy of duloxetine
did not differ between older and younger melancholic
patients irrespective of the old/young age threshold.
In the 6 studies that included an SSRI comparator, there
were no significant differences in baseline-to-endpoint
changes in efficacy measures between duloxetine and SSRI
treatment groups (Table 5). In addition, treatment-by-
therapy interactions for mean change in HAMD17 total
score, mean change in CGI-S score, and mean endpoint
Table 3: Mean changes from baseline to last observation in all studies and the subset of positive studies
Melancholic Status Mean Change (SD) p-valuea p-valueb
Duloxetine Placebo
HAMD17 Total Score
All Studies MEL (n = 1249) -8.97 (7.36) -6.57 (7.24) <.001
NON-MEL (n = 621) -8.25 (6.55) -6.20 (6.22) <.001 .651
Positive Studies MEL (n = 984) -9.83 (7.20) -7.03 (7.06) <.001
NON-MEL (n = 474) -9.15 (6.23) -6.47 (6.27) <.001 .781
CGI-Severity
All Studies MEL (n = 1251) -1.52 (1.25) -1.11 (1.21) <.001
NON-MEL (n = 621) -1.47 (1.23) -1.14 (1.19) .001 .511
Positive Studies MEL (n = 986) -1.62 (1.25) -1.16 (1.20) <.001
NON-MEL (n = 474) -1.54 (1.13) -1.15 (1.17) <.001 .679
PGI-Improvement† Mean (SD)
All Studies MEL (n = 1249) 2.67 (1.27) 3.07 (1.27) <.001
NON-MEL (n = 621) 2.71 (1.31) 3.17 (1.27) <.001 .865
Positive Studies MEL (n = 984) 2.64 (1.26) 3.09 (1.27) <.001
NON-MEL (n = 474) 2.70 (1.28) 3.18 (1.32) <.001 .912
a. p-value for duloxetine vs. placebo
b. p-value for treatment-by-melancholia status interaction
† Mean score (SD). Lower mean score indicates greater improvement.
Table 4: Mean changes from baseline to last observation by gender in melancholic patients
Gender Mean Change (SD) p-valuea p-valueb
Duloxetine Placebo
HAMD17 Total 
Score
Male (n = 386) -7.99 (7.04) -5.95 (7.13) .003 .932
Female (n = 863) -9.42 (7.46) -6.83 (7.29) <.001
CGI-Severity Male (n = 386) -1.41 (1.28) -0.97 (1.22) .001 .668
Female (n = 865) -1.57 (1.24) -1.17 (1.20) <.001
Mean (SD)
PGI-Improvement† Male (n = 385) 2.80 (1.27) 3.13 (1.23) .009 .877
Female (n = 864) 2.61 (1.26) 3.04 (1.29) <.001
a. p-value for duloxetine vs. placebo
b. p-value for treatment-by-gender interaction
† Mean score (SD). Lower mean score indicates greater improvement.BMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
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Table 5: Mean changes from baseline to last observation in active comparator studies
Melancholic Status Mean Change (SD) p-valuea p-valueb
Duloxetine SSRI
HAMD17 Total 
Score
MEL (n = 878) -8.85 (7.39) -8.60 (7.68) .709 .784
NON-MEL (n = 416) -8.18 (6.52) -7.59 (6.70) .897
CGI-Severity MEL (n = 880) -1.53 (1.26) -1.52 (1.33) .979 .865
NON-MEL (n = 416) -1.46 (1.24) -1.40 (1.24) .474
Mean (SD)
PGI-Improvement† MEL (n = 877) 2.67 (1.28) 2.64 (1.34) .484 .817
NON-MEL (n = 416) 2.64 (1.29) 2.57 (1.02) .077
a. p-value for duloxetine vs. SSRI
b. p-value for treatment-by-melancholia status interaction
† Mean score (SD). Lower mean score indicates greater improvement.
Mean changes in HAMD17 Maier subscale for melancholic patients receiving duloxetine (60 mg QD) or placebo Figure 1
Mean changes in HAMD17 Maier subscale for melancholic patients receiving duloxetine (60 mg QD) or placebo. ** p < .005 vs. 
placebo.
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PGI-I score were not statistically significant, indicating
that the relative efficacy of duloxetine and SSRIs did not
differ significantly between melancholic and non-melan-
cholic patients (Table 5).
Efficacy – focus studies
Analyses of mean changes from baseline to Week 9
(MMRM mean change) for melancholic patients in the
two focus studies (Studies 5 and 6) are summarized in
Table 6. Melancholic patients receiving duloxetine had
significantly greater improvement in mean HAMD17 total
score and HAMD17 Maier subscale compared with those
receiving placebo (p < .001). Significant differences from
placebo first occurred at Week 1 (Maier subscale, Figure 1)
or Week 2 (total score) and were present at all subsequent
visits. Significant advantages for duloxetine over placebo
for mean changes to Week 9 among melancholic patients
were also observed on the HAMD17 retardation and sleep
subscales, but not for the anxiety subscale (p = .230). On
both clinician-rated (CGI-S) and patient-rated (PGI-I)
assessments of global improvement, duloxetine-treated
melancholic patients had significantly greater mean
improvements compared with melancholics receiving
placebo (p < .001). Robustness of the MMRM results was
confirmed in that significant differences were also
observed in LOCF mean change analyses.
Mean changes from baseline (MMRM mean change) for
VAS overall pain were also assessed. Figure 2 shows a vis-
itwise plot of mean changes in VAS overall pain severity
for melancholic patients. For the main effect of treatment
(pooling results from all visits – interpreted similar to an
area under the curve analysis) duloxetine-treated
melancholic patients had significantly greater improve-
ment compared with placebo. Duloxetine's advantage
over placebo in treating the painful physical symptoms
did not vary substantially between patients with and with-
out melancholic features. However, the response profiles
were somewhat different in that response to placebo was
generally lower in patients with melancholic features
compared with non-melancholic patients. For example,
the mean percentage improvement in overall pain among
non-melancholic patients receiving placebo was 15.6%,
compared with a 0.5% worsening in overall pain among
placebo-treated melancholic patients.
Estimated probabilities (categorical MMRM analyses) of
remission at Week 9 were significantly higher for melan-
cholic patients treated with duloxetine (60 mg QD)
compared with placebo (44.4% vs. 24.7%, respectively; p
= .002). The estimated probability of response among
melancholic patients was 74.7% for duloxetine compared
with 42.2% for placebo (p < .001). The advantage of
duloxetine over placebo in remission and response rates
was also significant in LOCF analyses (p = .032 and p =
.002, respectively).
Discussion
The magnitude of duloxetine's advantage over placebo
was generally similar in melancholic and non-melan-
cholic patients. Treatment-by-melancholic status interac-
tions were not significant for any of the three assessed
efficacy measures (HAMD17 total score, CGI-S, PGI-I).
These results suggest that duloxetine's efficacy does not
differ substantially between melancholic and non-melan-
cholic patients. Furthermore, within the group of
melancholic patients, duloxetine's treatment effects were
similar in male and female patients (treatment-by-gender
interactions were not statistically significant). One excep-
tion was noted in the anxiety subscale of the HAMD17. In
Table 6: Mean changes from baseline to week 9 in melancholic patients (focus studies)
Mean Change (SE) p-value
Duloxetine 60 mg QD (n = 
153)
Placebo (n = 163)
HAMD17 Total Score -11.02 (0.65) -7.51 (0.61) <.001
Subscales
Maier -6.16 (0.36) -3.95 (0.34) <.001
Anxiety -2.65 (0.22) -2.29 (0.21) .230
Retardation -4.52 (0.26) -2.67 (0.24) <.001
Sleep -1.78 (0.17) -1.17 (0.16) .007
VAS Overall Paina -6.12 (-22.8) 0.13 (0.48) .002
CGI-Severity -1.84 (0.11) -1.30 (0.10) <.001
PGI-Improvementb 2.47 (0.11) 3.08 (0.11) <.001
CGI = Clinical Global Impression; HAMD = Hamilton Rating Scale for Depression; PGI = Patient Global Impression
a. Values are mean change (percentage mean change), and p value is from main effect of treatment
b. Mean score (SE). Lower mean score indicates greater improvement.BMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
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the two focus studies, duloxetine did not achieve separa-
tion from placebo in patients with melancholic features,
but demonstrated efficacy in non-melancholic patients.
The reason for the disparity in outcomes between melan-
cholic and non-melancholic patients on the HAMD17 anx-
iety subscale is unclear.
In previous studies, the prevalence of melancholic fea-
tures in populations of depressed outpatients has ranged
from 16% to 53%. The substantial variation in the
reported rates of melancholia may be a result of the
numerous criteria used to define melancholic features
over the past two decades, including DSM-III, DSM-III-R,
DSM-IV, and the Newcastle 1 Depression Rating Scale
(N1) [48]. In the present study of depressed outpatients,
the prevalence of melancholic features was substantially
higher (67.1%) than previous estimates, and merits fur-
ther comment. At baseline screening all patients were
required to meet DSM-IV criteria for MDD, while the pres-
ence of melancholic features (DSM-IV criteria) was deter-
mined using results from the MINI (further details are
provided in the Methods section). The high prevalence of
melancholic features was consistent across all 8 clinical
trials regardless of geographic location (two studies were
conducted in Eastern Europe, six were conducted in the
United States). Given the large number of investigative
sites (over 140 sites across the 8 studies), and the fact that
melancholic features were not used as an inclusion or
exclusion criterion in any of the studies, it is unlikely that
raters were artificially inflating the number of patients
classified as melancholic. A more likely explanation
appears to be that the screening method (i.e. the MINI
plus DSM-IV criteria) produced a substantial number of
false positive results with regard to melancholic features.
It is possible that the use of an alternative melancholia
screening tool, such as the CORE scale developed by
Parker et al [49], would have identified a smaller and
more well-defined group of melancholic patients. Thus, in
a study evaluating the CORE measure of melancholia
against the DSM-IV construct, the CORE criteria identified
Mean changes in VAS overall pain severity for melancholic patients receiving duloxetine (60 mg QD) or placebo Figure 2
Mean changes in VAS overall pain severity for melancholic patients receiving duloxetine (60 mg QD) or placebo. ** p < .005 vs. 
placebo.
-10
-8
-6
-4
-2
0
2
4
6
123456789
Placebo (n=163)
Duloxetine (60 mg QD; n=152)
M
e
a
n
 
C
h
a
n
g
e
 
i
n
 
V
A
S
 
O
v
e
r
a
l
l
 
P
a
i
n
**
**
Week
**BMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
Page 10 of 12
(page number not for citation purposes)
patients with neuroendocrine disturbance whereas DSM-
IV criteria did not [50]. In a wider context, the fact that
such a high proportion of patients in the current study
met DSM-IV criteria for melancholia may raise questions
regarding the validity of melancholia as a separate clinical
entity [50], and whether it should be considered simply as
a variant of MDD which differs only in severity [51,52].
Although the current results cannot directly address con-
cerns as to the validity of melancholia, the unusually high
proportion of melancholic patients identified at baseline
suggests that the use of the MINI together with DSM-IV
criteria may well be an inadequate screening tool for such
purposes.
There was no significant difference in age between melan-
cholic and non-melancholic patient groups, despite the
fact that melancholic features are more common in older
patients. Patients with melancholic features had
significantly lower mean body weight at baseline
compared to non-melancholics, with a between-group
difference of 3.6 kg (8.0 lbs). Since one of the DSM-IV cri-
teria for melancholic features is "significant anorexia or
weight loss", this result does not appear surprising. How-
ever, given that the melancholic cohort contained a signif-
icantly greater proportion of females when compared
with the non-melancholic group, the lower body weight
among melancholics may be an artifact of gender rather
than of MDD subtype. For example, in a recent study of
1694 depressed patients, Berlin et al reported that the
presence of melancholic features was not associated with
lower body mass index [53].
As expected, melancholic patients exhibited a greater
severity of illness at baseline compared with non-melan-
cholics, with a mean baseline HAMD17 score almost two
points higher (approximately one-half standard devia-
tion) in the melancholic group. Melancholic patients also
had significantly higher baseline CGI-S scores when com-
pared to those without melancholic features. Although
melancholic patients had a slightly higher overall pain
severity at baseline (as assessed using the self-rated VAS
measure of overall pain), the difference only approached
statistical significance and its clinical relevance is
questionable.
A frequent finding in placebo-controlled antidepressant
studies is that placebo responses among melancholic
patients are smaller than those observed in non-melan-
cholic patients [23-25,54], although this is not always the
case [55]. In the present assessment, mean changes in
HAMD17, CGI-S or PGI-I scores among both placebo- and
duloxetine-treated melancholic patients were slightly
larger than those of non-melancholic patients, resulting in
a very similar drug-placebo difference in both patient
groups. In measures of pain severity there was evidence of
greater placebo response among non-melancholic
patients; however, duloxetine's advantage over placebo
was similar in melancholic and non-melancholic patients,
since patients without melancholic features exhibited
more robust responses to both drug and placebo, when
compared with melancholic patients.
There does not appear to be a clear consensus as to which
class of antidepressant medication is most efficacious for
depressed patients exhibiting melancholic features. Some
studies have demonstrated advantages for TCAs over
SSRIs in the treatment of melancholia [29-32], and these
results have found support from patient-rated assess-
ments of antidepressant efficacy. When melancholic
patients were asked to judge the extent to which previous
antidepressant therapies had been effective, 38% of those
who had received TCAs rated them as moderately or
totally effective, compared with 22% of those who had
received SSRIs [56]. However, other studies have found no
significant differences in efficacy between SSRIs and TCAs
in melancholic patients [33,35], or in some cases superi-
ority of an SSRI (fluvoxamine) over a TCA (imipramine)
[34,57]. In the absence of clear evidence for superior effi-
cacy of any one class of medication, the safety and tolera-
bility profile of the SSRIs has led to their emergence as first
line treatment for melancholia. The present study found
no significant differences in efficacy between duloxetine
and SSRI comparators within the subgroup of melan-
cholic patients, although we note that the studies were not
powered to detect such differences. These results suggest
that pharmacological treatment of patients with melan-
cholic features should be assessed on a case-by-case basis,
and emphasize that distinct class effects have yet to be
demonstrated consistently within this group of patients.
Results from the present investigation must be considered
in light of several limitations. Firstly, this was a post-hoc
analysis of pooled clinical trial data. Although subgroup
analyses of efficacy assessments stratified by melancholic
status were pre-specified in each protocol, the pooling
strategies and some of the analyses conducted in the
present investigation were not pre-specified. Secondly,
while melancholic features were evaluated as part of the
MINI at study entry, specific melancholic features were
not an entry requirement and randomization was not
stratified by melancholic status. Furthermore, as discussed
previously in some detail, the MINI is not an ideal tool for
assessing the presence of melancholic features. Thirdly,
the HAMD17 scale has only limited capability to assess
improvement in melancholic symptoms. Anhedonia, one
of the key features of melancholia, is only assessed indi-
rectly as a part of question 7, while psychomotor agitation
is only partially addressed by question 9. Furthermore,
items such as diurnal variation in mood are not specifi-
cally measured by the HAMD17.BMC Psychiatry 2005, 5:1 http://www.biomedcentral.com/1471-244X/5/1
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Fourthly, the group of patients receiving the recom-
mended target dose of duloxetine (60 mg QD) could not
be compared head-to-head with SSRIs, as these two
studies did not feature active comparator treatment
groups. Finally, although duloxetine demonstrated signif-
icant advantage over placebo on a number of efficacy
measures, the individual studies were powered on the
basis of the primary outcome – mean change in HAMD17
total score. Therefore, results from other efficacy measures
should be viewed as secondary in nature. Together, these
limitations necessitate that the results from the present
investigation cannot be considered confirmatory. A pro-
spectively designed clinical trial will be required to con-
firm the results suggested by the current set of analyses.
Conclusions
In these analyses of pooled data, the efficacy of duloxetine
in patients with melancholic features did not differ
significantly from that observed in non-melancholic
patients. Additional prospectively designed clinical trials
evaluating duloxetine's efficacy in melancholic patients
will be required to substantiate the preliminary findings
described here.
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